Safety results of the Canadian Expanded Access Program (EAP) of palbociclib (PAL) plus letrozole (L) in postmenopausal patients (pts) with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) deemed appropriate candidates for first-line (1L) endocrine therapy (ET) with L.

被引：1
|
作者：
Joy, Anil A.
Verma, Shailendra
Provencher, Louise
Theall, Kathy Puyana
Lu, Dongrui
Dequen, Florence
Rayson, Daniel
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e12534
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12534
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Palbociclib (PAL) plus letrozole (L) as first-line (1L) therapy (tx) in postmenopausal Asian women with estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC)
    Im, S-A.
    Mukai, H.
    Park, I. H.
    Masuda, N.
    Shimizu, C.
    Kim, S. B.
    Im, Y-H.
    Ohtani, S.
    Bartlett, C. H.
    Lu, D. R.
    Mori, A.
    Gauthier, E.
    Finn, R. S.
    Toi, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Overall survival of palbociclib (PAL) plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the 1st line (1L) or 2nd line (2L) setting: A multicenter observational study
    Nakayama, T.
    Nagai, S. E.
    Hattori, M.
    Yoshinami, T.
    Masuda, H.
    Okamura, T.
    Watanabe, K-I.
    Tsuneizumi, M.
    Takabatake, D.
    Harao, M.
    Yasojima, H.
    Oshiro, C.
    Iwase, M.
    Yamaguchi, M.
    Sangai, T.
    Sasada, S.
    Ishida, T.
    Futamura, M.
    Kosaka, N.
    Masuda, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S368 - S368
  • [3] Palbociclib (PAL) plus letrozole (L) as first-line (1) therapy (tx) in estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Efficacy and safety across patient (pt) subgroups.
    Finn, Richard S.
    Dieras, Veronique
    Rugo, Hope S.
    Joy, Anil A.
    Moulder, Stacy L.
    Walshe, Janice Maria
    Mukai, Hirofumi
    Shparyk, Yaroslav V.
    Park, In Hae
    Mori, Ave
    Lu, Dongrui
    Gauthier, Eric Roland
    Gelmon, Karen A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) first-line advanced breast cancer (ABC) receiving palbociclib plus letrozole (P plus L)
    Dieras, V.
    Harbeck, N.
    Joy, A. A.
    Gelmon, K. A.
    Ettl, J.
    Verma, S.
    Lu, D.
    Gauthier, E. R.
    Schnell, P.
    Mori, A.
    Rugo, H. S.
    Finn, R. S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India
    Loi, Sherene
    Karapetis, Christos S.
    McCarthy, Nicole
    Oakman, Catherine
    Redfern, Andrew
    White, Michelle
    Khasraw, Mustafa
    Doval, Dinesh Chandra
    Gore, Vinod
    Alam, Mahmood
    Binko, Justin
    Lu, Dongrui Ray
    Kim, Sindy
    Boyle, Frances
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (06) : 560 - 569
  • [6] Ribociclib plus letrozole for first-line treatment of hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers
    Andre, Fabrice
    Stemmer, Salomon M.
    Campone, Mario
    Petrakova, Katarina
    Paluch-Shimon, Shani
    Yap, Yoon-Sim
    Marschner, Norbert
    Chan, Arlene
    Villanueva, Cristian
    Hart, Lowell L.
    Arteaga, Carlos L.
    Sonke, Gabe S.
    Grischke, Eva-Maria
    Alba, Emilio
    Nusch, Arnd
    Yardley, Denise A.
    Jakobsen, Erik
    Blau, Sibel
    Tolaney, Sara M.
    Su, Faye
    He, Wei
    Germa, Caroline
    Hortobagyi, Gabriel N.
    CANCER RESEARCH, 2017, 77
  • [7] First-line ribociclib plus letrozole in postmenopausal Asian women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2
    Yap, Y. S.
    Tseng, L-M.
    Blackwell, K. L.
    Cameron, D.
    Foo, S.
    Sriuranpong, V.
    Huang, C-S.
    Chao, T-Y.
    Kim, T-Y.
    Chen, S-C.
    Jung, K. H.
    Lee, K. S.
    Sohn, J-H.
    Kim, J. H.
    Hou, M-F.
    Han, Y.
    Souami, F.
    Dhuria, S.
    Miller, M.
    Verma, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] Impact of prior treatment on palbociclib plus letrozole (P plus L) efficacy and safety in patients (pts) with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) first-line advanced breast cancer (ABC): A PALOMA-2 subgroup analysis
    Finn, R. S.
    Gelmon, K. A.
    Ettl, J.
    Asselah, J.
    Castrellon, A.
    Ruiz Simon, A.
    Joy, A. A.
    Lu, D.
    Gauthier, E. R.
    Mori, A.
    Rugo, H. S.
    Dieras, V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Efficacy and safety of palbociclib (PAL) plus letrozole (LET) as first-line therapy in estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Findings by geographic region from PALOMA-2
    Gelmon, Karen A.
    Castrellon, Aurelio
    Joy, Anil A.
    Walshe, Janice M.
    Ettl, Johannes
    Mukai, Hirofumi
    Park, In Hae
    Lu, Dongrui R.
    Mori, Ave
    Bananis, Eustratios
    Dieras, Veronique
    Finn, Richard S.
    CANCER RESEARCH, 2018, 78 (04)
  • [10] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC)
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. S.
    Sonke, G. S.
    Paluch-Shimon, S.
    Campone, M.
    Blackwell, K.
    Andre, F.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D.
    Xuan, F.
    Souami, F.
    Miller, M.
    Germa, C.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2016, 27
12345